Bio & Pharma
Dong-A ST, UMass to jointly research for gene therapy
Both aim to target chronic inflammatory diseases with Adenovirus-associated virus-mediated treatment
By Nov 03, 2023 (Gmt+09:00)
1
Min read
Most Read
Macquarie eyes its 1st Korean data center valued around $722 mn
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
S.Korea's LS Materials set to boost earnings ahead of IPO process
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
POSCO gears up for carbon-free steelmaking with hydrogen
South Korea's Dong-A ST announced on Friday it has signed a joint research agreement with the University of Massachusetts (UMass) Chan Medical School in the United States for Adenovirus-associated virus(AAV)-mediated gene therapy.
Both sides plan to undertake joint research targeting chronic inflammatory diseases among immunological disorders.
Dong-A ST and UMass will examine the efficacy of gene therapies for chronic inflammatory diseases loaded onto AAV by the medical school. Subsequently, the school will evaluate the efficacy of the selected AAV candidates in mouse models, while Dong-A ST will do the same in animal models.
Dong-A ST stated that this joint research involves professors from UMass Medical School, including Prof. Guangping Gao, who has been researching gene therapy for over 30 years and has discovered AAV7, AAV8, and AAV9 for therapeutic development, and Prof. Jae-Hyuck Shim, an expert in genetic therapy for bone disorders.
"We have high hopes for the joint research and development conducted with the research team from UMass, a globally renowned institution in the field of AAV research," Dong-A ST CEO Park Jaehong said. "We will do our best to develop innovative new drugs for chronic inflammatory diseases and use this joint research as a foundation for future-oriented R&D in the gene therapy field."
Write to In-Hyuk Park at hyuk@hankyung.com
More to Read
Comment 0
LOG IN